Genetically modified CAR T-cells targeting CD19 have shown impressive ... focused on leveraging our experience in viral vector design and manufacture to efficiently bring innovative therapies ...

Vector BioMed (VBM), a leading lentiviral vector CDMO advancing access to gene therapies, will showcase its innovations at two major industry events this May: the International Society for Cell & Gene ...

Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell ...

ProBioGen inks agreement with Polpharma Biologics to provide high-performance cell line development services: Gdansk, Poland Friday, May 9, 2025, 17:00 Hrs [IST] ProBioGen, a Berl ...

The VDL is currently restructuring and not providing services at this time. For all request of viral vectors, please visit the Gene Vector Core Website or send an email to [email protected]. Since ...

The move bolsters the CDMO’s commitment to cell and gene therapy by incorporating advanced manufacturing and fill-finish ...

There is a consistent need from researchers to manufacture a cGMP virus to support the advancement of gene therapies.

They are non-integrating vectors so expression in dividing cells is progressively lost. First generation vectors may be suitable for applications where transient, high level activity is sufficient, ...

James Miskin brings 25 years of cell and gene therapy experience to an ... organization (“CDMO”) specializing in GMP viral vector manufacturing for clinical trials, announces the appointment ...

will outline the key steps required to transform the cell and gene therapy landscape, emphasizing rapid vector design, accelerated timelines to get to the clinic, and broader global access.